Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.9% – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares dropped 4.9% on Thursday . The company traded as low as $16.95 and last traded at $16.6010. Approximately 38,211 shares were traded during trading, a decline of 98% from the average daily volume of 2,146,871 shares. The stock had previously closed at $17.45.

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent research reports. HC Wainwright increased their price objective on shares of Dyne Therapeutics from $46.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Oppenheimer raised shares of Dyne Therapeutics from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $11.00 to $40.00 in a research report on Wednesday, December 10th. Royal Bank Of Canada raised their price target on shares of Dyne Therapeutics from $23.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Lifesci Capital upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Finally, Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a report on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.47.

Dyne Therapeutics Stock Performance

The stock has a 50-day moving average of $19.60 and a 200 day moving average of $15.37. The firm has a market capitalization of $2.39 billion, a P/E ratio of -4.57 and a beta of 1.32. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DYN. Y Intercept Hong Kong Ltd lifted its stake in shares of Dyne Therapeutics by 54.5% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 124,628 shares of the company’s stock valued at $1,186,000 after purchasing an additional 43,963 shares during the period. Arcadia Investment Management Corp MI lifted its stake in Dyne Therapeutics by 23.1% in the second quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock valued at $526,000 after buying an additional 10,350 shares during the period. Saturn V Capital Management LP acquired a new position in Dyne Therapeutics in the second quarter valued at about $13,856,000. Bryce Point Capital LLC bought a new position in Dyne Therapeutics during the second quarter worth about $115,000. Finally, TFG Asset Management GP Ltd acquired a new position in shares of Dyne Therapeutics during the 2nd quarter worth about $1,317,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.